By binding to RANKL with high affinity, denosumab prevents its interaction with the RANK receptor on osteoclast precursors, thereby inhibiting the formation of osteoclast-like giant cells and suppressing tumor-induced osteolysis. This evidence concerns the gene TNFSF11 and neoplasm.